Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)

16 novembre 2026 aggiornato da: University of Zurich

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)

This interventional prospective multicenter international study will include 54 patients with regionally metastatic (i.e. cN1 cM0) prostate cancer according to the NCCN criteria.

Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

This study is classified as risk category A according to ClinO, Art. 61, as stereotactic radiotherapy (SBRT) for regionally metastatic prostate cancer has been extensively evaluated in prospective interventional trials and is considered an established therapeutic modality.

Weekly CT- or MR-guided online adaptive SBRT to the prostate and elective pelvic lymph nodes with 5 × 5 Gy is, however, not yet routinely implemented for this specific patient population.

A diagnostic high field MRI during radiotherapy, e.g. week 3 is optional.

Follow-up is also according to standard of care (except for patient reported outcome measure using QLQ-C30 and QLQ-PR25 and a diagnostic MRI at 9 months after SBRT (optional), and 12 months in the case of an image non-complete response at 9 months (optional).

Panoramica dello studio

Stato

Non ancora reclutamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

54

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Baden-Würtemberg
      • Heidelberg, Baden-Würtemberg, Germania, 69120
        • University Clinic Heidelberg
        • Contatto:
          • Jürgen Debus
    • Canton of Zurich
      • Zurich, Canton of Zurich, Svizzera, 8091
        • University Hospital Zurich
        • Contatto:
          • Matthias Guckenberger
        • Contatto:
          • Tiuri Kroese

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion criteria include:

  • Regionally metastatic prostate cancer (cN1, cT1-cT3, Gleason 6-10, any PSA) according to NCCN guidelines consisting of ≤ 5 regional lymph node metastases
  • Good to moderate performance status (WHO 0-2)
  • Written informed consent.
  • A PSMA PET and multiparametric MRI is mandatory according to staging guidelines.
  • Age ≥ 18 years

Exclusion criteria include:

  • >5 regional lymph nodes

  • Patients with cT4 disease (tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall)

  • Previous radiotherapy to the pelvis or prostate

  • Previous radical prostatectomy

  • Large body size that would not fit into the MRI-simulator bore

  • Presence of distant metastases (i.e. cM1)

    • Non-regional lymph nodes (M1a):
    • Bone metastases (M1b)
    • Other sites (M1c)
  • Contraindications to CT or MR-adaptive SBRT (e.g., pacemakers, severe claustrophobia).

  • Severe comorbidities that may interfere with treatment or follow-up (e.g. inflammatory bowel disease).

  • Significant concomitant diseases (e.g. hepatic dysfunction, cardiovascular disease, etc.).

  • Inability to follow procedures or insufficient knowledge of project language, inability to give consent.

  • Participation in a clinical trial which might influence the results of this project.

  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

  • Severe genitourinary or gastrointestinal symptoms (e.g. recent urinary retention or diarrhea ≥ grade 3 or obstipation to CTCAE v.6.0).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Altro: Single Group Study

Assessment of weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy.

Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Feasibility- a successful delivery of CT or MR-informed SBRT per fraction
Lasso di tempo: from Day 1 of treatment up to 7 weeks until end of treatment

Feasibility will be assessed by recording whether each fraction of stereotactic body radiation therapy (SBRT), guided by computed tomography (CT) or magnetic resonance (MR) imaging, is successfully delivered according to the planned treatment parameters. Successful delivery is defined as completion of the planned fraction without protocol deviations or technical interruptions. Data will be summarized as the proportion of fractions successfully delivered per patient and overall. Every treatment fraction having passed the point of entry into the adaptive workflow will be analyzed for this endpoint.

from Day 1 of treatment up to 7 weeks until end of treatment
Safety - Adverse events
Lasso di tempo: ≥ 3 months to within 1 year after completion of SBRT

The presence of genitourinary or gastrointestinal toxicity of grade ≥ 3 within 1 year after completion of radiotherapy (according to CTCAE v5.0). Treatment-related discontinuation. and Subgroup analyses will be performed for patients with and without regional lymph node metastases (i.e., cN0 versus cN1).

≥ 3 months to within 1 year after completion of SBRT

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Biochemical progression-free survival
Lasso di tempo: from Day 1 up to 5 years after treatment

This will be determined from the start of therapy until the occurrence of PSA recurrence according to the Phoenix criteria i.e. post- therapeutic PSA nadir + 2 ng/ml

from Day 1 up to 5 years after treatment
Castration-resistant free survival
Lasso di tempo: from Day 1 up to 5 years after treatment

Castration-resistant free survival defined as cancer progression despite low (castrate) levels of testosterone (<50 ng/dL). Cancer progression is defined as:

  • Biochemical progression: ≥2 consecutive PSA rises (at least 1 week apart)
  • Radiologic progression: appearance of new lesions on imaging
from Day 1 up to 5 years after treatment
Patients Quality of Life EQ-5D-5L from the European Organisation for Research and Treatment of Cancer
Lasso di tempo: from Day 1 up to end of study until 5 years

Quality-of-life will be measured using the EQ-5D-5L questionnaire during and after treatment

All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

from Day 1 up to end of study until 5 years
Patients Quality of Life QLQ-C30 from the European Organisation for Research and Treatment of Cancer
Lasso di tempo: From Day 1 up to end of study (up to 5 years)

Quality of life will be measured using the EORTC QLQ-C30 questionnaire. This instrument includes functional scales, symptom scales, and a global health status/quality-of-life scale. All scores are linearly transformed to a 1-4 scale. For functional scales and global health status, higher scores indicate better functioning or quality of life, whereas for symptom scales/items, higher scores indicate greater symptom burden.

From Day 1 up to end of study (up to 5 years)
Adverse events
Lasso di tempo: from Day 1 until 5 years or end of Study

Genitourinary and Gastrointestinal toxicity measured with Common Terminology Criteria for Adverse Events (CTCAE)

from Day 1 until 5 years or end of Study
Patients overall survival
Lasso di tempo: from Day 1 until Progression or death whichever comes first until 5 years

defined from the start of therapy until death or censoring

from Day 1 until Progression or death whichever comes first until 5 years
Patient overall treatment - Patient treatment workflow duration (time from MRI scan start to completion of treatment)
Lasso di tempo: from Day 1 start of therapy, weekly until end of treatment up to 7 weeks

Patient will be asked from the start and end of MRI scan to start and end of treatment respectively, and for all steps from simulation to treatment delivery individually

from Day 1 start of therapy, weekly until end of treatment up to 7 weeks
Other Toxicities
Lasso di tempo: Day 1 of Treatment for up to 5 years or until death whichever comes first

Treatment-related toxicities other than the primary toxicity outcomes will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Other Toxicities will be evaluated during SBRT treatment and throughout follow-up for up to 5 years after completion of treatment or until patient death, whichever occurs first. The type, frequency, and severity (grade) of adverse events will be recorded according to CTCAE v5.0 criteria.

Day 1 of Treatment for up to 5 years or until death whichever comes first
Dosimetry difference
Lasso di tempo: from Day 1 of treatment start until end of treatment up to 7 Weeks

Dosimetry difference of the online adaptive plan compared to the original plan recalculated on the imaging of the day. Dosimetry difference is defined as difference in coverage of the planning target volume (PTV) or of one of the organs at risk e.g. bowel or rectum

from Day 1 of treatment start until end of treatment up to 7 Weeks
Anatomy changes assessed on magnetic resonance imaging (MRI)
Lasso di tempo: from Day 1 of treatment up to 7 weeks

Anatomical changes will be evaluated using serial magnetic resonance imaging (MRI) acquired during treatment and follow-up. Changes in relevant anatomical structures (e.g., target volume and surrounding organs at risk) will be assessed by comparing images obtained at baseline and subsequent imaging time points. Observed anatomical variations will be documented and summarized descriptively.

from Day 1 of treatment up to 7 weeks
Comparison of Patient treated and not treated
Lasso di tempo: from Day 1 until 5 Years of study or death

Comparison of number of patients not treated at all/not treated with all planned fractions in the CT or MR-informed workflow compared to those intended to be treated and categorization of patterns of failure within the CT or MR-informed workflow.

from Day 1 until 5 Years of study or death
Patient compliance
Lasso di tempo: from Day 1 until 5 Years / end of Study

Patient compliance will be measured by tracking a scheduled treatment sessions and adherence to the prescribed treatment protocol, including completion of all required procedures and instructions. Data will be collected throughout the treatment period and summarized as the proportion of scheduled sessions attended and procedures completed, as well as reasons for any missed sessions or deviations from the protocol.

from Day 1 until 5 Years / end of Study
Patient well being and comfort
Lasso di tempo: from Day 1 of treatment to weekly up to 7 weeks

Patients will be asked to report their comfort during and after simulation assess with a 0 to 10 numerical rating scales, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

from Day 1 of treatment to weekly up to 7 weeks
Physician decision certainty
Lasso di tempo: from Day1 of treatment to weekly up to 7 weeks

clinicians will be asked to report their clinical confidence with a 0 to 10 NRS, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

from Day1 of treatment to weekly up to 7 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Matthias Guckenberger, University of Zurich
  • Cattedra di studio: Matthias Guckenberger, Universitätsspital Zürich
  • Investigatore principale: Tiuri Kroese, University of Zurich

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 gennaio 2027

Completamento primario (Stimato)

1 luglio 2029

Completamento dello studio (Stimato)

1 gennaio 2033

Date di iscrizione allo studio

Primo inviato

11 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 maggio 2026

Primo Inserito (Effettivo)

15 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi